Vnitr Lek 2013, 59(7):612-617
Treatment of chronic hepatitis C virus infection at the beginning of a new era
- Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MUDr. Miroslav Zavoral, Ph.D.
After 2010 the therapy of chronic HCV infection entered a completely new era - the era that is marked with the gradual introduction of the so-called directly acting antivirals into treatment schemes of this serious disease. The term directly acting antivirals (DAA) covers low-molecular substances that inhibit viral non-structural proteins - enzymes involved in the HCV replication cycle. At present, the first 2 representatives of DAA, Boceprevir and Telaprevir, have been approved for chronic HCV infection indication. The synoptic article pays the greatest attention to these 2 representatives, along with mentioning some other substances that are under later phases of clinical development and are likely to be approved in the near future.
Keywords: chronic hepatitis C; pegylated interferon; ribavirin; boceprevir; telaprevir
Received: April 30, 2013; Published: July 1, 2013 Show citation
References
- Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
Go to original source... 
Go to PubMed... - Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217. Go to original source... Go to PubMed...
- Zeuzem S, Andreone P, Pol S. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428. Go to original source... Go to PubMed...
- Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206. Go to original source... Go to PubMed...
- Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416. Go to original source... Go to PubMed...
- Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024. Go to original source... Go to PubMed...
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264. Go to original source... Go to PubMed...
- Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444. Go to original source... Go to PubMed...
- Urbánek P, Husa P, Galský J et al. Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C (HCV). Gastroent Hepatol 2012; 26: 214-229.
- Lalezari LP, Nelson DR, Hyland RH et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study. Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24.-28. 4. 2013. Abstract 845.
- Sulkowski MS, Gardiner DF, Rodroguez-Torres M et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24.-28. 4. 2013. Abstract 1417.
- Kowdley KV, Lawitz E, Poordad F et al. Safety and efficacy of interferon-free regimens of ABT-450/R, ABT-267, ABT-333 ± ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24.-28. 4. 2013. Abstract 3.
- Kowdley KV, Lawitz E, Poordad F et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. Abstracts 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston 9.-13. 11. 2012. Abstract LB-1.